title: Intestinal transit of a glucose bolus and incretin kinetics: a mathematical model with application to the oral glucose tolerance test.
abstract: The rate of appearance (R(a)) of exogenous glucose in plasma after glucose ingestion is presently measured by tracer techniques that cannot be used in standard clinical testing such as the oral glucose tolerance test (OGTT). We propose a mathematical model that represents in a simple way the gastric emptying, the transport of glucose along the intestinal tract, and its absorption from gut lumen into portal blood. The model gives the R(a) time course in terms of parameters with a physiological counterpart and provides an expression for the release of incretin hormones as related to glucose transit into gut lumen. Glucose absorption was represented by assuming two components related to a proximal and a distal transporter. Model performance was evaluated by numerical simulations. The model was then validated by fitting OGTT glucose and GLP-1 data in healthy controls and type 2 diabetic patients, and useful information was obtained for the rate of gastric emptying, the rate of glucose absorption, the R(a) profile, the insulin sensitivity, and the glucose effectiveness. Model-derived estimates of insulin sensitivity were well correlated (r = 0.929 in controls and 0.886 in diabetic patients) to data obtained from the euglycemic hyperinsulinemic clamp. Although the proposed OGTT analysis requires the measurement of an additional hormone concentration (GLP-1), it appears to be a reasonable choice since it avoids complex and expensive techniques, such as isotopes for glucose R(a) measurement and direct assessment of gastric emptying and intestinal transit, and gives additional correlated information, thus largely compensating for the extra expense.
authors.affiliation: Department of Computer and System Science, University of Rome Sapienza, Rome, Italy. salinari@dis.uniroma1.it
authors.forename: Serenella
authors.initials: S
authors.lastname: Salinari
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bertuzzi
authors.forename: Geltrude
authors.initials: G
authors.lastname: Mingrone
mesh_terms: D000328:Adult; D000465:Algorithms; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition / Q000502:physiology; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism; D005772:Gastrointestinal Transit / Q000502:physiology*; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism*; D005951:Glucose Tolerance Test / Q000379:methods* / Q000706:statistics & numerical data*; D006801:Humans; D054795:Incretins / Q000378:metabolism*; D007263:Infusions, Parenteral; D007408:Intestinal Absorption / Q000502:physiology; D007413:Intestinal Mucosa / Q000378:metabolism; D007700:Kinetics; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D015203:Reproducibility of Results; D051269:Sodium-Glucose Transporter 1 / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D054795:Incretins; C495674:SLC5A1 protein, human; D051269:Sodium-Glucose Transporter 1; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005947:Glucose